Follow-up
death, gynecological primary tumors, Leipzig’s local cancer
PSEUDOMYXOMA PERITONEI, MESOTHELIOMA, DISEASE COURSE
For the current analysis, we stopped documenting new PIPACs on the 2nd of June 2020. Follow-up was completed by the 10th of December 2020. This was necessary in 84 patients (whose disease course and—when applicable—death had not already been documented in the hospital’s patient registry). We were able to complete the follow-ups in 16 patients with the help of Leipzig’s local cancer registry. Of the 74 letters sent out to the respective physicians responsible for further treatment, 42 (57%) were answered.By the end of this study period, only six patients were still undergoing PIPAC therapy. The most common reason for ending the treatment was patients’ death (Patients, whose median overall survival (OS) was the shortest, were those who had gynecological primary tumors: 136 days after their first scheduled PIPAC. The group of “others” showed the longest median OS (mesothelioma, pseudomyxoma peritonei, and CUP), namely 604 days. Kaplan–Meier analysis revealed that the median OS of all patients combined was 264 days (interquartile range 108–586) (Supplementary Table 1).